{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T17:50:55Z","timestamp":1777139455464,"version":"3.51.4"},"reference-count":14,"publisher":"Bentham Science Publishers Ltd.","issue":"1","license":[{"start":{"date-parts":[[2018,6,29]],"date-time":"2018-06-29T00:00:00Z","timestamp":1530230400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/legalcode"}],"content-domain":{"domain":["openophthalmologyjournal.com","benthamopen.com"],"crossmark-restriction":true},"short-container-title":["TOOPHTJ"],"published-print":{"date-parts":[[2018,6,29]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>The Tafluprost\/Timolol Fixed Combination (TTFC) has demonstrated efficacy and safety in reducing Intraocular Pressure (IOP). However, direct comparisons of switching from tafluprost to TTFC are limited.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>To investigate the efficacy and safety of switching from tafluprost to TTFC in patients with Primary Open-Angle Glaucoma (POAG).<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Thirty-four eyes (34 patients) with POAG that did not achieve adequate IOP reduction on tafluprost were switched to TTFC with no washout period. IOP, systolic\/diastolic blood pressure and pulse rate were measured 1 and 3 months later and compared with baseline values. All participants were asked about specific adverse reactions after 1 and 3 months of treatment. Patients also completed a questionnaire about preference and adherence after 1 month of treatment.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Mean IOP after 1 and 3 months was significantly lower than at baseline (14.2 \u00b1 2.1 mmHg and 14.1 \u00b1 2.3 mmHg, respectively, vs 16.0 \u00b1 2.0 mmHg, P &lt; 0.0001). Systolic\/diastolic blood pressure and pulse rate were not significantly different from baseline after 1 and 3 months. The questionnaire indicated that the frequency of missing a dose was not different before (27.3%) or after (18.2%) switching to TTFC (P = 0.2371). There were five reports of adverse reactions (14.7%), including a corneal epithelium disorder, ocular irritation, skin irritation at the wrist, and chest pain. Two patients (5.9%) withdrew because of adverse reactions.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Switching from tafluprost to TTFC achieved IOP control safely and was well accepted by patients.<\/jats:p>\n                <\/jats:sec>","DOI":"10.2174\/1874364101812010121","type":"journal-article","created":{"date-parts":[[2018,7,9]],"date-time":"2018-07-09T01:15:46Z","timestamp":1531098946000},"page":"121-126","update-policy":"https:\/\/doi.org\/10.2174\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Efficacy and Safety of Switching from Tafluprost to a Tafluprost\/Timolol Fixed Combination in Patients With Primary Open-Angle Glaucoma"],"prefix":"10.2174","volume":"12","author":[{"given":"Kenji","family":"Inoue","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeaki","family":"Ueda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyoko","family":"Ishida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Goji","family":"Tomita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref1","unstructured":"The Japan Glaucoma Society Guidelines for Glaucoma (4th Edition) \n                    2018."},{"key":"ref2","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1097\/IJG.0b013e3181815421","volume":"18","author":"Djafari F.","year":"2009","unstructured":"Djafari F, Lesk MR, Harasymowycz PJ, Desjardins D, Lachaine J. \n                    Determinants of adherence to glaucoma medical therapy in a long-term patient population. \n                    J Glaucoma  \n                    2009; \n                    18\n                    (3)\n                    : 238-43.","journal-title":"J. Glaucoma"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.ophtha.2015.09.005","volume":"123","author":"Li T.","year":"2016","unstructured":"Li T, Lindsley K, Rouse B, et al. \n                    Comparative effectiveness of first-line medications for primary open-angle glaucoma: A systematic review and network meta-analysis. \n                    Ophthalmology  \n                    2016; \n                    123\n                    (1)\n                    : 129-40.","journal-title":"Ophthalmology"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.2147\/OPTH.S63760","volume":"8","author":"Schmier J.K.","year":"2014","unstructured":"Schmier JK, Hulme-Lowe CK, Covert DW. \n                    Adjunctive therapy patterns in glaucoma patients using prostaglandin analogs. \n                    Clin Ophthalmol  \n                    2014; \n                    8\n                    : 1097-104.","journal-title":"Clin. Ophthalmol."},{"key":"ref5","first-page":"1185","volume":"30","author":"Kuwayama Y.","year":"2013","unstructured":"Kuwayama Y. \n                    DE-111 Collaborative Trial Group. Phase III double-masked study of fixed combination tafluprost 0.0015%\/timolol 0.5% (DE-111) versus tafluprost 0.0015% alone or given concomitantly with timolol 0.5% in primary open angle glaucoma and ocular hypertension \n                    Atarashii Ganka  \n                    2013; \n                    30\n                    : 1185-94.","journal-title":"Atarashii Ganka"},{"key":"ref6","first-page":"133","volume":"32","author":"Kuwayama Y.","year":"2015","unstructured":"Kuwayama Y. \n                    DE-111 Collaborative Trial Group. A long-term, open-label study of fixed combination tafluprost 0.0015%\/timolol 0.5% (DE-111) in patients with open-angle glaucoma or ocular hypertension. \n                    Atarashii Ganka  \n                    2015; \n                    32\n                    : 133-43.","journal-title":"Atarashii Ganka"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.2147\/OPTH.S128453","volume":"11","author":"Pillunat L.E.","year":"2017","unstructured":"Pillunat LE, Erb C, Ropo A, Kimmich F, Pfeiffer N. \n                    Preservative-free fixed combination of tafluprost 0.0015% and timolol 0.5% in patients with open-angle glaucoma and ocular hypertension: Results of an open-label observational study. \n                    Clin Ophthalmol  \n                    2017; \n                    11\n                    : 1051-64.","journal-title":"Clin. Ophthalmol."},{"key":"ref8","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1007\/s40123-016-0057-3","volume":"5","author":"Takagi Y.","year":"2016","unstructured":"Takagi Y, Osaki H, Yamashita T, Kai Y. \n                    Prospective observational post-marketing study of tafluprost 0.0015%\/timolol 0.5% combination ophthalmic solution for glaucoma and ocular hypertension: short-term efficacy and safety. \n                    Ophthalmol Ther  \n                    2016; \n                    5\n                    (2)\n                    : 191-206.","journal-title":"Ophthalmol. Ther."},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1007\/s12325-014-0163-3","volume":"31","author":"Pfeiffer N.","year":"2014","unstructured":"Pfeiffer N, Traverso CE, Lorenz K, et al. \n                    A 6-month study comparing efficacy, safety, and tolerability of the preservative-free fixed combination of tafluprost 0.0015% and timolol 0.5% versus each of its individual preservative-free components. \n                    Adv Ther  \n                    2014; \n                    31\n                    (12)\n                    : 1228-46.","journal-title":"Adv. Ther."},{"key":"ref10","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1089\/jop.2013.0229","volume":"30","author":"Holl\u00f3 G.","year":"2014","unstructured":"Holl\u00f3 G, Hommer A, Ant\u00f3n L\u00f3pez A, Ropo A. \n                    Efficacy, safety, and tolerability of preservative-free fixed combination of tafluprost 0.0015%\/timolol 0.5% versus concomitant use of the ingredients. \n                    J Ocul Pharmacol Ther  \n                    2014; \n                    30\n                    (6)\n                    : 468-75.","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"ref11","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1185\/03007995.2014.972500","volume":"31","author":"Holl\u00f3 G.","year":"2015","unstructured":"Holl\u00f3 G, Ropo A. \n                    Intraocular pressure decrease with preservative-free fixed and unfixed combination of tafluprost and timolol in pseudoexfoliative glaucoma. \n                    Curr Med Res Opin  \n                    2015; \n                    31\n                    (1)\n                    : 13-6.","journal-title":"Curr. Med. Res. Opin."},{"key":"ref12","first-page":"1761","volume":"30","author":"Ueda K.","year":"2013","unstructured":"Ueda K, Tonouchi A, Fukano Y. \n                    Tafluprost 0.0015%\/timolol 0.5% combination ophthalmic solution (DE-111 Ophthalmic solution) formulation design and intraocular penetration in rats. \n                    J Eye  \n                    2013; \n                    30\n                    : 1761-6.","journal-title":"J. Eye"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"771","DOI":"10.2147\/OPTH.S31085","volume":"6","author":"Inoue K.","year":"2012","unstructured":"Inoue K, Fujimoto T, Higa R, et al. \n                    Efficacy and safety of a switch to latanoprost 0.005% + timolol maleate 0.5% fixed combination eyedrops from latanoprost 0.005% monotherapy. \n                    Clin Ophthalmol  \n                    2012; \n                    6\n                    : 771-5.","journal-title":"Clin. Ophthalmol."},{"key":"ref14","first-page":"1559","volume":"29","author":"Aoki Y.","year":"2012","unstructured":"Aoki Y, Nagumo H, Inoue K, Tomita G. \n                    Ocular hypotensive effect and safety of travoprost 0.004%\/timolol maleate 0.5% fixed combination, switched from travoprost 0.004% alone for 3 months. \n                    Atarashii Ganka  \n                    2012; \n                    29\n                    : 1559-62.","journal-title":"Atarashii Ganka"}],"container-title":["The Open Ophthalmology Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/openophthalmologyjournal.com\/contents\/volumes\/V12\/TOOPHTJ-12-121\/TOOPHTJ-12-121.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/openophthalmologyjournal.com\/contents\/volumes\/V12\/TOOPHTJ-12-121\/TOOPHTJ-12-121.xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/openophthalmologyjournal.com\/contents\/volumes\/V12\/TOOPHTJ-12-121\/TOOPHTJ-12-121.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,15]],"date-time":"2019-04-15T02:33:39Z","timestamp":1555295619000},"score":1,"resource":{"primary":{"URL":"https:\/\/openophthalmologyjournal.com\/VOLUME\/12\/PAGE\/121\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,29]]},"references-count":14,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,6,29]]}},"alternative-id":["TOOPHTJ-12-121"],"URL":"https:\/\/doi.org\/10.2174\/1874364101812010121","relation":{},"ISSN":["1874-3641"],"issn-type":[{"value":"1874-3641","type":"print"}],"subject":[],"published":{"date-parts":[[2018,6,29]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2017-12-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-4-20","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-5-24","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-6-29","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}